16 September 2026 editorial review · Trial
MiniMed 670G pivotal in-home hybrid closed-loop study: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: No additional discrepancy identified in the reviewed summary/design/endpoint and eligibility fields. Existing sponsor or historical claims are not all independently certified by this protocol comparison.
Registry: NCT02463097. Endpoint reviewed: Change in A1C (Baseline and 3 months). Eligibility reviewed: Age 14 Years to 75 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Additional source access: Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.; Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes..